Format

Send to

Choose Destination
See comment in PubMed Commons below
Hum Vaccin. 2011 Mar;7(3):349-56. Epub 2011 Mar 1.

Emerging antibody products and Nicotiana manufacturing.

Author information

1
Mapp Biopharmaceutical, Inc., San Diego, CA, USA. kevin.whaley@mappbio.com

Abstract

Antibody based products are not widely available to address multiple global health challenges due to high costs, limited manufacturing capacity, and long manufacturing lead times. Nicotiana-based manufacturing of antibody products may now begin to address these challenges as a result of revolutionary advances in transient expression and altered glycosylation pathways. This review provides examples of emerging antibody-based products (mucosal and systemic) that could be competitive and commercially viable when the attributes of Nicotiana-based manufacturing (large scale, versatile, rapid, low cost) are utilized.

PMID:
21358287
PMCID:
PMC3166493
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center